

Honglin Zhu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1784430/publications.pdf>

Version: 2024-02-01

45
papers

1,200
citations

471509

17
h-index

414414

32
g-index

47
all docs

47
docs citations

47
times ranked

1617
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA Expression Abnormalities in Limited Cutaneous Scleroderma and Diffuse Cutaneous Scleroderma. <i>Journal of Clinical Immunology</i> , 2012, 32, 514-522.	3.8	140
2	MicroRNA-21 in Scleroderma Fibrosis and its Function in TGF- β 2- Regulated Fibrosis-Related Genes Expression. <i>Journal of Clinical Immunology</i> , 2013, 33, 1100-1109.	3.8	140
3	The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts. <i>Immunity</i> , 2021, 54, 1002-1021.e10.	14.3	106
4	Whole-genome transcription and DNA methylation analysis of peripheral blood mononuclear cells identified aberrant gene regulation pathways in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2016, 18, 162.	3.5	103
5	Autoantigen Microarray for High-throughput Autoantibody Profiling in Systemic Lupus Erythematosus. <i>Genomics, Proteomics and Bioinformatics</i> , 2015, 13, 210-218.	6.9	83
6	MicroRNAs: their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma. <i>Experimental and Molecular Medicine</i> , 2013, 45, e41-e41.	7.7	51
7	TGF β 2 promotes fibrosis by MYST1-dependent epigenetic regulation of autophagy. <i>Nature Communications</i> , 2021, 12, 4404.	12.8	40
8	MicroRNA-202-3p regulates scleroderma fibrosis by targeting matrix metalloproteinase 1. <i>Biomedicine and Pharmacotherapy</i> , 2017, 87, 412-418.	5.6	36
9	The Fibrosis and Immunological Features of Hypochlorous Acid Induced Mouse Model of Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 1861.	4.8	33
10	Using multi-omics methods to understand dermatomyositis/polymyositis. <i>Autoimmunity Reviews</i> , 2017, 16, 1044-1048.	5.8	32
11	Neutrophil-derived exosome from systemic sclerosis inhibits the proliferation and migration of endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2020, 526, 334-340.	2.1	27
12	The role of metabolism in the pathogenesis of systemic sclerosis. <i>Metabolism: Clinical and Experimental</i> , 2019, 93, 44-51.	3.4	24
13	HSP25 down-regulation enhanced p53 acetylation by dissociation of SIRT1 from p53 in doxorubicin-induced H9c2 cell apoptosis. <i>Cell Stress and Chaperones</i> , 2016, 21, 251-260.	2.9	21
14	Integration of Genome-Wide DNA Methylation and Transcription Uncovered Aberrant Methylation-Regulated Genes and Pathways in the Peripheral Blood Mononuclear Cells of Systemic Sclerosis. <i>International Journal of Rheumatology</i> , 2018, 2018, 1-19.	1.6	21
15	The roles of neutrophil serine proteinases in idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , 2018, 20, 134.	3.5	21
16	Systematic approach to understanding the pathogenesis of systemic sclerosis. <i>Clinical Genetics</i> , 2017, 92, 365-371.	2.0	20
17	PGC-1 α regulates autophagy to promote fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1227-1233.	0.9	19
18	The profiles of miRNAs and lncRNAs in peripheral blood neutrophils exosomes of diffuse cutaneous systemic sclerosis. <i>Journal of Dermatological Science</i> , 2020, 98, 88-97.	1.9	19

#	ARTICLE	IF	CITATIONS
19	Interleukin-33 in Systemic Sclerosis: Expression and Pathogenesis. <i>Frontiers in Immunology</i> , 2018, 9, 2663.	4.8	18
20	The function of ncRNAs in rheumatic diseases. <i>Epigenomics</i> , 2019, 11, 821-833.	2.1	18
21	The role of IFI35 in lupus nephritis and related mechanisms. <i>Modern Rheumatology</i> , 2017, 27, 1010-1018.	1.8	17
22	The role and mechanism of cathepsin G in dermatomyositis. <i>Biomedicine and Pharmacotherapy</i> , 2017, 94, 697-704.	5.6	16
23	Engrailed 1 coordinates cytoskeletal reorganization to induce myofibroblast differentiation. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	16
24	Tumor necrosis factor antagonists in the treatment of multicentric reticulohistiocytosis: Current clinical evidence. <i>Molecular Medicine Reports</i> , 2016, 14, 209-217.	2.4	13
25	Integrated comparison of the miRNAome and mRNAome in muscles of dermatomyositis and polymyositis reveals common and specific miRNA-mRNAs. <i>Epigenomics</i> , 2019, 11, 23-33.	2.1	13
26	Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1385-1395.	5.6	13
27	The Role of Immune Cells in the Pathogenesis of Idiopathic Inflammatory Myopathies. , 2021, 12, 247.		13
28	Lipid Metabolism Profiles in Rheumatic Diseases. <i>Frontiers in Pharmacology</i> , 2021, 12, 643520.	3.5	12
29	Plasma exosomal RNAs have potential as both clinical biomarkers and therapeutic targets of dermatomyositis. <i>Rheumatology</i> , 2022, 61, 2672-2681.	1.9	12
30	Global analysis of protein expression in muscle tissues of dermatomyositis/polymyositis patients demonstrated an association between dysferlin and human leucocyte antigen A. <i>Rheumatology</i> , 2019, 58, 1474-1484.	1.9	11
31	Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2021, 137, 2403-2416.	1.4	11
32	Ubiquitination in Scleroderma Fibrosis and Its Treatment. <i>Frontiers in Immunology</i> , 2018, 9, 2383.	4.8	10
33	Investigation into the cause of mortality in 49 cases of idiopathic inflammatory myopathy: A single center study. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 885-889.	1.8	9
34	Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy. <i>Rheumatology International</i> , 2017, 37, 585-592.	3.0	8
35	Deep sequencing reveals a DAP1 regulatory haplotype that potentiates autoimmunity in systemic lupus erythematosus. <i>Genome Biology</i> , 2020, 21, 281.	8.8	8
36	The Expression of Cytokine Profiles and Related Receptors in Idiopathic Inflammatory Myopathies. <i>Frontiers in Pharmacology</i> , 2022, 13, 852055.	3.5	7

#	ARTICLE	IF	CITATIONS
37	Increased Serum Matrix Metalloproteinase-9 Levels are Associated with Anti-Jo1 but not Anti-MDA5 in Myositis Patients. , 2019, 10, 746.		6
38	The altered metabolism profile in pathogenesis of idiopathic inflammatory myopathies. Seminars in Arthritis and Rheumatism, 2020, 50, 627-635.	3.4	6
39	The Functional Roles of RNAs Cargoes Released by Neutrophil-Derived Exosomes in Dermatomyositis. Frontiers in Pharmacology, 2021, 12, 727901.	3.5	6
40	Discovery of Key Genes in Dermatomyositis Based on the Gene Expression Omnibus Database. DNA and Cell Biology, 2018, 37, 982-992.	1.9	5
41	Mortality trend of inpatients with connective tissue diseases: 2005-2014. Journal of Central South University (Medical Sciences), 2017, 42, 927-933.	0.1	4
42	Machine Learning Algorithms Identify Clinical Subtypes and Cancer in Anti-TIF1 ⁺ Myositis: A Longitudinal Study of 87 Patients. Frontiers in Immunology, 2022, 13, 802499.	4.8	4
43	X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc). Annals of the Rheumatic Diseases, 2021, 80, 1048-1056.	0.9	3
44	Contributions of Immune Cells and Stromal Cells to the Pathogenesis of Systemic Sclerosis: Recent Insights. Frontiers in Pharmacology, 2022, 13, 826839.	3.5	3
45	Risk factors for serious infections in inpatients with systemic lupus erythematosus. Journal of Central South University (Medical Sciences), 2021, 46, 704-710.	0.1	0